Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from an animal study demonstrating its topical Ketamine formulation's effectiveness in reducing neuropathic nerve pain. The study showed a significant reduction in both allodynia and hyperalgesia using its patented delivery system in partnership with Zylo Therapeutics. Notably, day seven and day nine evaluations showed no erythema or swelling, indicating a favorable safety profile, which is promising for upcoming toxicology studies. CEO Eric Weisblum emphasized the potential benefits for patients with Fibromyalgia and Rheumatoid Arthritis.
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from animal studies demonstrating the effectiveness and reduced toxicity of its novel liposomes using a subcutaneous delivery method for anti-arthritic agents. CEO Eric Weisblum stated that this method is well-suited for targeted drug delivery, enhancing efficacy and minimizing systemic toxicity. Previous studies with intravenous injections showed promising results, and the new findings indicate that subcutaneous administration is comparable in performance, with potential for even greater effectiveness.
Silo Pharma (OTCQB: SILO) announced an expansion of its Commercial Evaluation License Agreement with the University of Maryland Baltimore for next-generation Liposomal Peptides aimed at treating autoimmune diseases. Positive results from pre-clinical tests in arthritis models were highlighted, showing significant therapeutic effects of specific peptides (NQR and RGD). The global market for autoimmune disease therapeutics is projected to exceed $150 billion by 2025, bolstering Silo's prospects for growth and investment potential.
Silo Pharma, Inc. (OTCQB: SILO) has successfully dosed patients with Parkinson's disease in a study in collaboration with the University of California San Francisco (UCSF). This research aims to examine the effects of psilocybin on inflammatory markers in these patients. The study is part of UCSF's Translational Psychedelic Research (TrPR) Program, which investigates the impact of psychedelics on brain health. CEO Eric Weisblum highlighted this milestone, expressing optimism about the forthcoming results and future patient cohorts.
Silo Pharma (OTCQB: SILO) announced the production of its first batch of liposomes for a preclinical study targeting anti-arthritic activity through its SPU-21 compound. This study will be conducted by Frontage Laboratories. The CEO, Eric Weisblum, emphasized that this development advances the research on SPU-21, which has potential applications in autoimmune diseases like rheumatoid arthritis (RA). The liposomes are designed to enhance drug delivery and effectiveness while reducing toxicity.
Silo Pharma, Inc. (OTCQB: SILO) has partnered with Frontage Laboratories to advance its Central Nervous System Peptide, SPU-16, and Joint Homing Peptide, SPU-21, technologies toward clinical application. This agreement aims to facilitate a Pharmacokinetic Study in animals, which will analyze doses and plasma samples. CEO Eric Weisblum highlighted the potential of these peptides to enhance therapeutic effects while reducing systemic toxicity, with applications in treating central nervous system and autoimmune diseases.
Silo Pharma, a developmental stage biopharmaceutical company, announced its partnership with IBN to enhance corporate communications. This collaboration aims to leverage IBN's extensive investor distribution network to raise awareness for Silo's innovative therapeutic solutions targeting PTSD, Alzheimer’s, and other neurological disorders. Silo has established research agreements with leading universities, including studies on ketamine and psilocybin for Parkinson’s disease and inflammation. This partnership underscores Silo's commitment to advancing medical research and developing transformative treatments.
Silo Pharma (OTC QB: SILO) announced the extension of its exclusive option agreement with the University of Maryland to explore joint-homing peptides for treating rheumatoid arthritis and other autoimmune diseases. This technology aims to enhance therapeutic delivery to diseased joints, improving treatment efficacy while minimizing systemic toxicity. CEO Eric Weisblum highlighted the potential of these peptides as a revolutionary drug delivery platform, emphasizing the need for innovative therapeutics for rare diseases.
Silo Pharma, Inc. (OTCQB: SILO) announced the engagement of Donohoe Advisory Associates for consulting services related to a potential NASDAQ up-listing. This strategic move aims to enhance visibility and attract a broader investor base. CEO Eric Weisblum emphasized that listing on NASDAQ could increase liquidity for shareholders, although approval and compliance with listing requirements are not guaranteed. Silo Pharma is focused on developing psychedelic therapies for conditions like depression and PTSD, seeking transformative solutions for patients.
Silo Pharma, Inc. (OTCQB: SILO) announced the issuance of U.S. Patent No. 11,174,287 for a novel homing peptide aimed at enhancing therapeutic targeting in the central nervous system (CNS). This advancement could improve pharmacological treatments, allowing for lower dosages and reduced side effects. CEO Eric Weisblum expressed optimism about expanding their intellectual property (IP) portfolio and the potential for this technology to transform treatment options for CNS disorders. The patent emphasizes the importance of targeting neuroinflammation in CNS tissues.